Respectfully Dave, the bit I don't get is why you are so committed to this company.
I understand you have been invested since at least pre-2019. At that time, IMU was all about its B-cell platform and was a company that "sold at or after Phase 2". So you do all the research and you believe in both the B-cell approach to attacking cancer and IMU's approach to commercialise it. But then it doesn't succeed.
Next IMU is on to CF33. Is it just coincidence that you researched the next best cancer cure (assuming b-cell products don't make it) and came up with CF33? And it just so happened that this is what IMU did next?
Then when CF33 doesn't progress as hoped, onto Azer-cel we go. Along with the changed IMU management strategy of "we can do Phase 3 and commercialise it ourselves". Again, just coincidence that if B-cell fails and CF33 fails, CAR T is the way to go? And you simultaneously agree that the strategy about how best to commercialise in this space, accorded with the change in IMU Management's strategy?
That's the bit I don't get about those that have researched (like you) and those that claim to have researched (like TB) being so committed to this company. If true research was being done in prioritising one's investments, how's it possible that the answer always comes out "Imugene" given the massive changes to the company's focus and strategy over the past 5 years?
Its seems more like blind faith. And even the fan club agree that Hopper's treatment of retail shareholders is poor. So blind faith in a company that treats retail shareholders poorly?
So many better options. So many better management teams. And all available to those (like you) with the smarts to understand the science ...
- Forums
- ASX - By Stock
- IMU
- Wher is Ben, Davy, Zior ?
IMU
imugene limited
Add to My Watchlist
18.2%
!
1.3¢

Wher is Ben, Davy, Zior ?, page-73
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M |
Open | High | Low | Value | Volume |
1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 5795292 | 1.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.3¢ | 3258567 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 5735292 | 0.012 |
35 | 10497532 | 0.011 |
118 | 35980571 | 0.010 |
37 | 19431668 | 0.009 |
13 | 4220748 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.013 | 3078567 | 8 |
0.014 | 10063029 | 39 |
0.015 | 6593187 | 20 |
0.016 | 6224494 | 27 |
0.017 | 7006978 | 10 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online